Drug Trial Radar · NCT06492954
Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Mar 2027
Primary completion
Jun 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- Emory UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Genentech, Inc.
- First posted
- Jul 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to determine the safety and tolerability of combined Atezolizumab, stereotactic body radiation therapy (SBRT), and surgical resection of pulmonary metastases in patients with pulmonary recurrence of osteosarcoma
Conditions
- Osteosarcoma
- Pulmonary Recurrence of Osteosarcoma
Interventions
Surgical ResectionProcedure
Removal of all lung nodules, including the radiated nodule, per the standard of care for osteosarcoma patients with lung metastasis.
Stereotactic Body Radiation Therapy (SBRT)Radiation
Dose level 1: 8 Gy\* 3 (Total 24 Gy) Dose level 2: 18 Gy\* 3 (Total 54 Gy)
AtezolizumabDrug
For subjects \<18 years of age at the time of enrollment, Atezolizumab will be administered IV on Day 1 of each 21-day cycle at a dose of 15 mg/kg (maximum dose of 1200 mg). Subjects ≥ 18 years old will receive a flat dose of 1200 mg IV on Day 1 of each 21-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Dose limiting toxicity at Dose Level 1Time frame: Baseline, end of 1 year
- Number of participants with Dose limiting toxicity at Dose Level 2Time frame: Baseline, end of 1 year
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Chilldren's Healthcare of Atlanta
Atlanta, Georgia · Recruiting
UT MD Anderson
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.